Articles tagged with Clinical Trials
A recent study published in The Journal of the Alzheimer's Association found that lecanemab, a new Alzheimer's-modifying drug, was less effective in female patients compared to males. The Phase 3 clinical trial showed a significant benefit in males, but little to no benefit in females, with the cause of the difference still unknown.
A Phase 1 clinical trial is enrolling up to 55 healthy adults to test the safety and immunogenicity of a candidate Lassa vaccine. The trial aims to prevent Lassa fever, a viral hemorrhagic disease that can cause permanent hearing loss.
Researchers at NIH identified characteristic symptoms of topical steroid withdrawal (TSW), including elevated nicotinamide adenine dinucleotide (NAD+) levels, which can be diagnosed using provisional criteria. TSW treatment may involve mitochondrial complex I-blocking drugs, such as metformin or berberine.
Fidaxomicin and fecal microbiota transplantation are effective treatments for Clostridioides difficile infection, reducing recurrence rates. Emerging strategies like vaccines, bacteriophage therapies, and AI-based risk models hold promise for better management and prevention of CDI.
A combination therapy of FTH-001 (serabelisib) and FTH-003 (sapanisertib) with paclitaxel is being investigated in a Phase 2 trial for patients with advanced or recurrent endometrial cancer. The trial aims to target the PI3K/AKT/mTOR pathway, which is frequently mutated in cancer.
Recent research suggests that some invasive cancers diagnosed in early-stage breast cancer may not need immediate surgery, highlighting the importance of more precise screening methods for DCIS. The COMET trial found that at least half of invasive breast cancers take years to progress or may never progress at all.
The Study of Tecovirimat for Mpox (STOMP) trial found that tecovirimat did not reduce the time to clinical resolution of clade II mpox lesions or improve pain control. The antiviral drug was shown to be safe but ineffective in treating clade II mpox.
A major clinical trial has identified ensitrelvir as an effective medication to prevent symptomatic COVID-19 in people exposed within households. The trial showed a 67% reduction in risk of illness among participants taking the antiviral compared to those given a placebo.
Researchers are conducting a first-in-human clinical trial to test a modified herpes virus that targets spinal cord nerve cells to treat neurogenic bladder. The therapy, EG110A, aims to block sensory nerve signals causing involuntary bladder contractions and incontinence.
A new study found that Black Americans are more willing to participate in medical studies led by Black doctors and researchers. Diversifying clinical trial leadership could improve enrollment of underrepresented groups and ensure the benefits and risks of treatments are understood across populations.
Researchers are enrolling 35 infants with tracheobronchomalacia in an eight-year study to test the safety and efficacy of a customized, 3D-printed bioresorbable airway splint. The device aims to help children with severe forms of the disease breathe easier and potentially extend their lifespan.
A Phase 1 clinical trial is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson's disease, in which a patient's stem cells are reprogrammed to replace dopamine cells. The trial uses autologous stem cell transplantation, avoiding immunosuppressive treatments, and has enrolled three patients so far.
Researchers are conducting a clinical trial to find the optimal combination of pain management tools for patients undergoing mastectomy procedures. The study will enroll approximately 100 patients and examine various combinations of pectoralis nerve blocks, non-opioid analgesics, and administration methods.
A Phase 2 clinical trial found that a neoadjuvant chemo-immunotherapy regimen achieved a 53% deep response rate, exceeding historical data with chemotherapy alone. The treatment approach led to impressive survival outcomes and fewer toxic side effects in patients with advanced HPV-negative head and neck cancer.
The Mount Sinai Hospital has become the first in the US to perform a deep brain stimulation (DBS) implantation procedure as part of a clinical trial investigating its effectiveness for treatment-resistant depression. The study aims to gather evidence on the impact of DBS systems developed by healthcare company Abbott.
A polypill programme combining a statin and three blood pressure lowering drugs could prevent thousands of heart attacks and strokes annually. The approach would be a flagship strategy for disease prevention rather than treatment.
A landmark study reveals that bacterial vaginosis is a sexually transmitted infection, causing infertility and premature births. Treating both partners simultaneously achieves significantly higher cure rates than current practice.
Targeted alpha therapy shows promise in treating resistant NETs, offering a precision tool for patients exhausted by conventional treatments. Early preclinical trials have delayed tumour growth with minimal toxicity, while clinical studies have reported high disease control rates.
A new stem cell therapy, CALEC, has been successfully tested on 14 patients with blinding cornea injuries, achieving a high proportion of complete or partial success rates. The treatment was found to be safe and effective, with no serious events occurring in either the donor or recipient eyes.
A recent study found that the NIH provides critical funding for pediatric clinical trials in diseases not prioritized by industry. Pediatric research in asthma and lung diseases has been chronically under-funded, highlighting the need for increased funding.
Researchers at University Hospitals Seidman Cancer Center have successfully repurposed fenofibrate, a cholesterol drug, to treat HPV+ cancers. The study found that fenofibrate restores the function of key tumor suppressor gene p53 and reactivates immune cells, offering a potential targeted therapy for these cancers.
A new clinical trial will use MDMA in combination with Prolonged Exposure therapy to enhance treatment outcomes for individuals with PTSD. Researchers believe MDMA shows potential in improving PTSD symptoms by increasing neuroplasticity and processing traumatic memories.
The project aims to improve the quality of life for patients with end-stage heart failure and their caregivers through a nurse-led intervention. The study will also track hospitalization rates, patient well-being, and gain a better understanding of end-of-life care.
A new study found that nearly 20% of cancer patients in middle-stage drug trials receive treatment that later gets FDA approval. This has important implications for drug development and clinical trial recruitment.
A novel bone marrow transplant process has been shown to be safe and curative for adults with sickle cell disease, offering a viable alternative to recent gene therapy products. The treatment, which uses a 'half-matched' donor, results in high cure rates and low side effects, making it a more accessible option for patients.
A recent study published in CANCER suggests that higher levels of physical activity may lessen and even eliminate survival disparities among colon cancer survivors. Cancer survivors who regularly exercised achieved better subsequent survival rates than those seen in the matched general population, with a 3.1% lower risk at year three.
A new home-based intervention has been shown to reduce unplanned hospital admissions among older adults with mild frailty by 35%. The service, which includes personalized visits and tailored support, also leads to small improvements in wellbeing and reduces hospital costs.
A new University of Cincinnati trial is comparing two types of omega-3 supplements, LPC-DHA and TAG-DHA, to slow or prevent dementia progression in elderly adults. Researchers aim to investigate whether LPC-DHA supplementation increases CSF DHA levels and improves cognitive function.
A cohort study found that patients with obesity undergoing joint replacement who experienced significant weight loss after initiating anti-obesity medications had a lower risk of 5-year and 10-year revision. This suggests that safe and sustainable weight loss may improve implant survivorship in obese patients.
The article reviews additive manufacturing technology for biomedical metals, enabling customized implants with precise internal structures. It highlights the integration of AI and 4D printing, addressing challenges in production costs, regulatory compliance, and post-processing.
New UCLA-led research finds that Paxlovid does not significantly reduce COVID-19 hospitalization and mortality among vaccinated older adults. The study suggests that Paxlovid's potential effect on COVID-19 hospitalization in vaccinated older adults is four times weaker than originally reported.
A new mobile health app-based intervention, BEST-U, is expanding to train non-mental health professionals in delivering the treatment. The 11-week program has shown 'most participants were fully recovered from their eating disorder' at the University of Kansas.
A recent Lancet article revealed that durvalumab combined with radiation therapy offers no benefits for patients with head and neck cancer who cannot receive cisplatin. However, a new clinical trial is underway to test the use of a heavy metal to enhance radiation therapy, providing potential new options for these patients.
A long-term study found that Roux-en-Y gastric bypass outperforms sleeve gastrectomy in treating obesity, with patients losing more excess body mass index. The Swiss Multicenter Bypass or Sleeve Study demonstrated the superiority of Roux-en-Y gastric bypass over sleeve gastrectomy for patient weight loss.
Groundbreaking research from the CLEAR study reveals that greater tumor shrinkage improves survival outcomes for patients with advanced renal cell carcinoma. The lenvatinib and pembrolizumab combination regimen demonstrates significant long-term benefits, including enhanced effectiveness of subsequent treatments.
Researchers are testing noninvasive electrical stimulation of the spinal cord to treat major depressive disorder. The trial, funded by the National Institute of Mental Health, aims to confirm whether this method reduces signaling in specific pathways related to depression.
Researchers found that radiation combined with immune checkpoint inhibitors durvalumab and tremelimumab resulted in durable responses allowing for bladder preservation in localized MIBC patients. The study showed a high efficacy rate of 93% complete response rate, with 84% overall survival rate after two years.
Researchers analyzed data from three trials and found nerinetide provided a clinically significant benefit to patients. The findings suggest that treating early, fast, and administering the drug can lead to improved patient outcomes.
Researchers at Mass General Brigham used a generative AI tool to screen patients for a heart failure clinical trial, significantly improving speed and efficiency compared to manual screening. The study found that the AI-assisted screening process screened 458 eligible patients compared to 284 in the manual group.
A new clinical trial will evaluate whether adding ketamine to standard treatment can improve outcomes for patients suffering from status epilepticus. The trial, called KESETT, hopes to determine whether ketamine can terminate the seizures in more patients than current treatments.
Researchers found that olpasiran significantly lowers lipoprotein(a) levels by over 95% and reduces oxidized phospholipids, which promote atherosclerosis. The study also showed no significant effects on inflammatory markers.
A single-dose breakthrough: PfSPZ-LARC vaccines offer high-level protection against malaria. By leveraging genetic engineering, the vaccine harnesses weakened parasites that replicate in the liver but halt progression to the blood stage.
A new mechanical heart pump, BrioVAD, is being tested against the current standard, HeartMate 3, in a national study. The trial aims to enroll 780 participants with advanced heart failure and will compare the two devices head-to-head.
Researchers at TUM have developed a new therapeutic approach combining dietary therapy with fecal microbiome transfer to sustain inflammation-free states in Crohn's disease patients. The study found that the gut microbiome changes as a result of dietary therapy contribute to treatment success.
A new clinical trial at UVA is testing an innovative AI-powered device designed to improve automated insulin delivery, aiming to simplify diabetes management. The trial will evaluate the 'Bolus Priming System with Reinforcement Learning' technology in adult participants with Type 1 Diabetes.
Researchers at MD Anderson Cancer Center have made significant advancements in treating oligometastatic prostate cancer, advanced urothelial cancer, and triple-negative breast cancer. Personalized risk-based screening is also being explored as a tool to reduce cancer deaths.
Researchers report that eating increasingly higher doses of peanut butter enabled 100% of children with peanut allergy who initially tolerated half a peanut to consume three tablespoons without an allergic reaction. The therapy could potentially fulfill an unmet need for about half of children with peanut allergy, who already can toler...
UCalgary researchers confirm that endovascular thrombectomy (EVT) is not effective for patients with blockages in medium-sized blood vessels. The ESCAPE-MeVO clinical trial found no improvement in outcomes for these patients compared to standard care. EVT was previously shown to improve patient outcomes after large-vessel strokes.
A new drug-free intervention targets the root cause of progressive loss of neural function in SMA by gradually reawakening functionally silent motor neurons. Early results show improved leg muscle strength and walking in adults with SMA, regardless of symptom severity.
Researchers at the University of Cincinnati presented studies on intracerebral hemorrhage treatment eligibility, finding only 3% of patients are eligible for a minimally invasive procedure. Additionally, a study found racial disparities in stroke recovery, with Black individuals experiencing worse functional outcomes after ischemic str...
A phase 1 trial of a personalized cancer vaccine for patients with stage III or IV clear cell renal cell carcinoma showed a positive response in all nine patients, with no higher-grade side effects reported. The vaccine generated a successful anti-cancer immune response and kept patients cancer-free at the time of data cut-off.
A cluster trial found salt substitution to be safe, with significant reductions in stroke recurrence and death rates among patients. The study supports large-scale implementation of this low-cost intervention as a major public health gain.
A study from the University of Gothenburg found that testosterone increases damage following a heart attack by increasing white blood cell release from bone marrow. This affects both men and women, but has a greater impact on male hearts.
A $10.8 million trial will enroll 600 patients aged 60+ to determine whether a hip replacement or internal fixation surgery is better for certain types of hip fractures. The study's patient-focused approach aims to inform clinical guidelines and help patients make informed decisions about their care.
Researchers have identified a targeted therapy that could bring relief to people living with lichen planus, a chronic inflammatory skin condition. The treatment, baricitinib, selectively blocks specific inflammatory pathways, reducing inflammation and suppressing the overactive immune response that contributes to the disease.
A new study adds weight to the safety and effectiveness of a gene therapy for hypophosphatasia, a rare inherited disorder that causes abnormal bone development. The treatment, AAV8-TNAP-D10, has shown promising results in mice models, with female mice achieving improvements in bone and teeth at lower doses.
A new study published in The Lancet Digital Health found that AI-supported breast cancer screening increased the detection of early-stage invasive cancers by 24% compared to traditional screening. AI also identified pre-cancerous lesions with a 51% higher rate, without increasing false positives.
A new study from the University of Birmingham found that digoxin is more effective than beta-blockers in reducing adverse events and hospital admissions for older patients with atrial fibrillation. This could lead to significant cost savings for the UK National Health Service, estimated at £102 million per year.
The NIH-funded clinical trial aims to evaluate the safety and ability of AV-1 to lessen symptoms in people suffering from dengue. The study will expose adult volunteers to a weakened strain of dengue virus and administer AV-1 at various doses.
The BP-CATCH trial found significant racial and ethnic disparities in pediatric counseling for children with high blood pressure, but no disparities were observed among those with or without obesity. The study highlights the need to address these disparities to provide equitable care to all patients.